TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144

8-K filing — INSULET CORP (PODD)

Filed: 2026-09-21 AccNo: 0001193125-26-396779 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet's Q2 Omnipod revenues grew 23.8% at constant currency with expanding global adoption, particularly for its Omnipod 5 automated insulin delivery system. The company raised 2026 international guidance and is progressing on next-generation products including Omnipod 6. However, intense competition, macroeconomic pressures, and supply chain risks could limit future margin expansion and profitability.

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.